Emergence of blaOXA-23 and blaOXA-58 carbapenemase-encoding genes in multidrug-resistant Acinetobacter baumannii isolates from University Hospital of Annaba, Algeria

Touati, Meriem; Diène, Seydina M.; Racherache, Abdelkarim; Dekhil, Mazouz; Djahoudi, Abdelghani; Rolain, Jean‐Marc

doi:10.1016/j.ijantimicag.2012.03.017

Cited by 39 publications

(26 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In central Italy, an interesting replacement of bla OXA-58 with bla OXA-23 belonging to EC-II has recently been established (18,19) and a similar abrupt shift has also been reported in Greece and Algeria, where 72.4% and 92% of the carbapenemresistant isolates tested harbored the bla OXA-23 gene (20,21), while the bla OXA-58 gene was predominant in those countries half a decade ago. All of the bla OXA-23 genes from Italy and Greece were located within Tn2006 transposons, either chromosomally or in plasmids.…”

mentioning

confidence: 60%

First Report of an OXA-23 Carbapenemase-Producing Acinetobacter baumannii Clinical Isolate Related to Tn 2006 in Spain

Espinal

Macià

Roca

et al. 2013

Antimicrob Agents Chemother

View full text Add to dashboard Cite

A carbapenem-resistant Acinetobacter baumannii clinical isolate belonging to European clone II and sequence type 2 was recovered from a patient in the Son Espases hospital in Mallorca, Spain. Genetic analysis showed the presence of the bla OXA-23 gene in association with the widely disseminated transposon Tn2006. This is the first reported identification of A. baumannii carrying bla OXA-23 in Spain.A cinetobacter baumannii is responsible for hospital outbreaks, and it is considered one of the most important nosocomial pathogens causing bacteremia, pneumonia, and other respiratory and urinary tract infections (1, 2). The abilities to acquire resistance mechanisms and to persist in the environment for long periods of time make this pathogen difficult to eradicate from the clinical setting (3, 4). The resistance of A. baumannii isolates to carbapenems is on the rise mainly in association with a variety of combined mechanisms, among which the production of acquired carbapenem-hydrolyzing OXA-type class D ␤-lactamases (CHDLs), OXA-23 in particular, has been identified worldwide (2).Here we report the first case of OXA-23 in an A. baumannii clinical isolate in Spain and in association with the widely spread Tn2006 transposon.OXA-23 was identified in a clinical isolate from a 59-year-old male patient admitted to the Department of Pneumology at the Son Espases hospital in Mallorca, Spain, in February 2010 because of increased dyspnea, coughing, chills, and purulent secretions during the previous 3 days. The patient was born in Portugal and had lived in Palma de Mallorca since 1998, although he had traveled to Portugal and France during the previous year. The patient had been hospitalized in Lisbon between 7 and 23 December 2009 and then again in another hospital between 26 December 2009 and 8 January 2010. He was a former smoker and had needed multiple hospital admissions because of exacerbations of chronic obstructive pulmonary disease. His regular medication included bronchodilators but no antibiotics. On the second day after admission, A. baumannii was isolated from his sputum and the patient was empirically treated with levofloxacin (500 to 750 mg/ day) but switched to intravenous colistin (2 to 3 MU/8 h) after 6 days because of susceptibility test results. The patient improved and was discharged for specialized home care. After the initial isolation, periodic sputum cultures were taken for several months with no further isolation of the strain.A. baumannii isolate AB 308 was initially identified by MicroScan and confirmed by matrix-assisted laser desorption ionization-time of flight mass spectrometry (Bruker Daltonics GmbH, Leipzig, Germany). Antibiotic susceptibilities were determined by MicroScan (Siemens) for most antimicrobial agents, except colistin and tigecycline, which were determined by Etest (AB bioMérieux, Solna, Sweden). These results were interpreted according to CLSI guidelines (5). The AB 308 isolate was resistant to amikacin (Ͼ256 g/ml), ceftazidime (Ͼ128 g/ml), tetracycline, ciprofloxacin, gentamic...

show abstract

mentioning

confidence: 60%

First Report of an OXA-23 Carbapenemase-Producing Acinetobacter baumannii Clinical Isolate Related to Tn 2006 in Spain

Espinal

Macià

Roca

et al. 2013

Antimicrob Agents Chemother

View full text Add to dashboard Cite

show abstract

“…OXA-24-like is also a widely disseminated cluster, however at a lesser prevalence than OXA-23-like [5]. In Algeria, Oxa-23-like and OXA-24-like were previously reported in Eastern and Western Algeria [31,35,38] and just recently in a hospital in Algiers [39].…”

Section: Discussionmentioning

confidence: 86%

High prevalence of multidrug-resistance in Acinetobacter baumannii and dissemination of carbapenemase-encoding genes blaOXA-23-like, blaOXA-24-like and blaNDM-1 in Algiers hospitals

Khorsi

Messai

Hamidi³

et al. 2015

Asian Pacific Journal of Tropical Medicine

View full text Add to dashboard Cite

show abstract

“…In subsequent studies, blaOXA-58 and blaOXA-23 like genes were described in A. baumannii with ISAba1, being found upstream to provide the needed promoter genes, some of these strains belonging to the rec A-27 genotype. 87 Bakour et al 9 Table S1). …”

Section: Algeriamentioning

confidence: 99%

The Molecular Epidemiology and Genetic Environment of Carbapenemases Detected in Africa

Sekyere

Govinden

Essack

2016

Microbial Drug Resistance

View full text Add to dashboard Cite

Research articles describing carbapenemases and their genetic environments in Gram-negative bacteria were reviewed to determine the molecular epidemiology of carbapenemases in Africa. The emergence of resistance to the carbapenems, the last resort antibiotic for difficult to treat bacterial infections, affords clinicians few therapeutic options, with a resulting increase in morbidities, mortalities, and healthcare costs. However, the molecular epidemiology of carbapenemases throughout Africa is less described. Research articles and conference proceedings describing the genetic environment and molecular epidemiology of carbapenemases in Africa were retrieved from Google Scholar, Scifinder, Pubmed, Web of Science, and Science Direct databases. Predominant carbapenemase genes so far described in Africa include the blaOXA-48 type, blaIMP, blaVIM, and blaNDM in Acinetobacter baumannii, Klebsiella pneumoniae, Enterobacter cloacae, Citrobacter spp., and Escherichia coli carried on various plasmid types and sizes, transposons, and integrons. Class D and class B carbapenemases, mainly prevalent in A. baumannii, K. pneumoniae, E. cloacae, Citrobacter spp., and E. coli were the commonest carbapenemases. Carbapenemases are mainly reported in North and South Africa as under-resourced laboratories, lack of awareness and funding preclude the detection and reporting of carbapenemase-mediated resistance. Consequently, the true molecular epidemiology of carbapenemases and their genetic environment in Africa is still unknown.

show abstract

Emergence of blaOXA-23 and blaOXA-58 carbapenemase-encoding genes in multidrug-resistant Acinetobacter baumannii isolates from University Hospital of Annaba, Algeria

Cited by 39 publications

References 5 publications

First Report of an OXA-23 Carbapenemase-Producing Acinetobacter baumannii Clinical Isolate Related to Tn 2006 in Spain

First Report of an OXA-23 Carbapenemase-Producing Acinetobacter baumannii Clinical Isolate Related to Tn 2006 in Spain

High prevalence of multidrug-resistance in Acinetobacter baumannii and dissemination of carbapenemase-encoding genes blaOXA-23-like, blaOXA-24-like and blaNDM-1 in Algiers hospitals

The Molecular Epidemiology and Genetic Environment of Carbapenemases Detected in Africa

Contact Info

Product

Resources

About